AstraZeneca will be listed on the stock market in the United States but will retain its base in the United Kingdom.

AstraZeneca plans to list on the New York Stock Exchange to attract more investors, but will also continue trading in the London market and retain its UK headquarters. The company said in a statement on Monday that the new shares will replace AstraZeneca's existing American Depositary Receipts in the US. CEO Pascal Soriot has been critical of the regulatory system in the UK and is concerned that the country is falling behind the US and China in competitiveness. Pharmaceutical companies are becoming increasingly disappointed with the UK government's efforts to revitalize the life sciences industry, questioning everything from the number of clinical trials to new drug reimbursement policies. Soriot is outspoken about his dissatisfaction with the UK's refusal to expand the use of AstraZeneca's breast cancer drug Enhertu to a wider range of patients. The breakdown of price negotiations for this cancer drug reflects the widespread controversy over adjustments to the way regulatory agencies assess the value of new drugs.